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Summary 
A paradigm of pharmacological adrenalectomy of 
pregnant rats and fetuses in utero is described. A 
regimen of twice daily metyrapone injections 
(10mg/100gm body weight), results in marked 
depression of serum corticosterone in pregnant and 
in fetal rats without surgical trauma and stress. 
The technique should be useful in a wide variety of 
studies involving the developing brain-adrenal axis. 
The mechanisms controll ing corticotropin releasing-hormone (CRH) 
gene expression in the developing rat brain have not been defined. 
The onset of messenger RNA (CRH-mRNA) synthesis occurs on the 17th 
fetal day (1,2), and progresses through the late fetal period. CRH- 
mRNA decreases markedly around the time of birth (1,2), and remains 
comparatively low during the first postnatal week. Whether the 
onset and the hiatus in CRH gene expression are intrinsic, 
constitutively regulated phenomena, or are modulated via negative 
feedback by circulating ACTH or corticosterone (presumably acting 
via their respective receptors,) is unknown. Changes in 
corticosteroid receptor number or type at the level of the 
pituitary have been invoked as a possible underlying mechanism (3). 
This study was designed to examine for the effects of eliminating 
the negative corticosterone feedback on the brain-adrenal axis in 
the fetal rat. Our goal was to achieve functional fetal 
adrenalectomy without the accompanying stress and trauma associated 
with surgical ablation in utero. The model should be useful in the 
study of the regulation of CRH gene expression in the developing 
rat brain. 
Materials and Methods 
Timed-pregnancy Sprague-Dawley derived rats, weighing less than 
350 grams, were obtained from Zivic-Mil ler (Zelienople, PA). Rats 
were kept on a 12 hour light/ dark cycle and fed and watered ad 
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l ibitum. Pregnancy was dated by the presence of a vaginal  plug 
which was cons idered to be day O. Pharmacolog ica l  adrenalectomy 
schedule was started on the 14th, 15th, or 16th day of pregnancy, 
and cont inued for 24, 48 or 72 hours: An imals  were injected 
subcutaneous ly  wi th  DMSO vehic le  or metyrapone (Sigma, St. Louis, 
MO) on a 12 hour schedule at 0800 h and 2000 h. Metyrapone, i0 
mg/kg dose, was in jected up to the morn ing  of sacrif ice, when it 
was fo l lowed by a i0 mg/kg dose of aminog luthet imide  (a b locker  of 
cholestero l  convers ion to 20- a lpha cholesterol ) ,  in vehicle, at 
0915h. An additonal  group was not in jected to control  for the 
ef fects  of handl ing and DMSO. 
Rats were decapi tated at 1000h and uter i  harvested immediately. 
Maternal  and fetal (fetal day 18 and 19 only) t runk blood was 
obta ined on days 15-18. Fetuses' b lood was pooled from with in  a 
l itter. L i t ter  s ize and pup weight  were assessed for exper imental  
and control  groups. Blood was centr i fuged immediate ly  for 30 
minutes  at 4000 G and serum kept frozen at -80°C unt i l  assayed. 
Hormone Assays: 
Cor t icosterone was assayed in fetal and maternal  b lood using a 
commercia l  rad io immunoassay kit  (ICN, Irvine, CA). ACTH was 
determined in both extracted and nonextracted serum using a 
rad io immunoassay  developed by Pennisula,  (Belmont, CA). As no 
s ign i f icant  d i f ferences between extracted and nonextracted plasma 
were found in pre l iminary  studies, samples were not extracted in 
subsequent  assays. Sens i t iv i ty  ranges for cor t icosterone and ACTH 
were 0.025 and 0.008 ng per  tube (0.05 and 0.08 ng/ml), 
respect ively.  Coef f ic ient  of var iat ion  for the cor t icosterone assay 
was <15%, and that for the ACTH assay was <10%. 
Stat is t ica l  Analyses: Samples were subjected to analyses of mean 
and standard deviat ion, and the s ign i f icance of d i f ferences between 
group means was assessed by student 's  t-test. Probabi l i ty  levels 
are indicated in parentheses.  
Resul ts  
Tox ic i ty  of the Reqimen: L i t ter  s ize and mean pup weight  of rats 
in jected wi th  vehic le  alone and of those in jected wi th  metyrapone 
are shown in Table I. There was no s ign i f icant  change in l i tter 
size, suggest ing no resorpt ion of pups even after  72 hours of 
pharmaco log ica l  adrenalectomy.  Likewise, no s ign i f icant  change in 
mean pup weight  was observed. The mean weight  of pups of rats 
in jected wi th  DMSO was not d i f ferent  from that of pups of untreated 
pregnant  rats. The d i f ference between plasma cort icosterone,  on the 
18th day, of un in jected contro ls  (34.6 ~ 8.4 mcg/dl) and DMSO- 
in jected rats (52.5 ~ 12.5 mcg/dl) ,  was not s ignif icant.  
E f fect  of Dharmacolou ica l  adrena lectomy on maternal  and fetal 
cor t i costerone levels: Cor t icosterone levels in DMSO and 
metyrapone- in jec ted  rats dur ing the th i rd week of pregnancy are 
compared in f igure i. Pharmacolog ica l  adrena lectomy decreases serum 
cor t icosterone levels 85 to 95%. This ef fect  of pharmacologica l  
adrena lectomy is seen after  24 hours  and does not d imin ish by 72 
hours  (f igure 2). Table 1 shows the ef fect  of pharmacologica l  
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adrenalectomy on serum corticosterone of fetuses on the 18th day. 
On the 19th fetal day plasma corticosterone was 47.5 ~ 3 mcg/dl 
for controls, and 7 ~ 2 mcg/dl for fetuses of metyrapone treated 
rats. 
TABLE I 
Effects of Pharmacological Adrenalectomy on Fetal Litter Size, 
Weight and Serum Corticosterone. 
Parameter Control Metyrapone-treated 
Fetal weight 
18th day (gm) 
1.44 + 0.2 
n=3 l~tters 
1.44 + 0.3 
n=6 l~tters 
Litter size ii + 2.1 12 + 2.4 
18th day (n) n=3--1itters n=6--1itters 
Corticosterone 
18th day (mcg/dl) 
30.2 + 3.7 5.9 + 1.6 
n=7 pools n=5 pools 
Values given indicate mean ~ standard deviation. 
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Fig. 1 
Serum corticosterone in pregnant rats, effects of 
pharmacological adrenalectomy. Pharmacological 
adrenalectomy was achieved by metyrapone injections 
as described in the text. All plasma corticosterone 
levels of treated animals were signif icantly 
different than those of controls (p = 0.001-0.0035). 
Effect of pharmacological adrenal~ctomy on ACTH levels in fetal 
and preanant rats: Plasma levels of ACTH in pregnant rats injected 
with DMSO or with metyrapone are shown in Table II. A 3-fold 
increase is evident following metyrapone administration. A 
parallel, metyrapone-induced increase of serum ACTH levels in rat 
fetuses is also seen. 
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TABLE II 
Effect of Pharmacological Adrenalectomy on Serum ACTH 
Pregnancy/gestation 
day 
Vehicle injected 
ng/ml 
16th day, adult 
Metyrapone injected 
ng/ml 
17th day, adult 
505 _+ 63 (n=3) 1,220 +_ 665 (n=3) 
506 + 127 (n=3) 1,466 + 102 (n=2) 
18th day, adult 488 + 57 (n=7) 2,007 + 666 (n=3) 
18th day, fetus 325 + 184 (n=4) 1,139 + 680 (n=3) 
(p<0.05, except for fetus, where p = 0.19). 
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Fig. 2 
Time course of corticosterone response to 
pharmacological adrenalectomy. Metyrapone injection 
regimen is described in the text. Plasma 
corticosterone levels of treated rats at all time 
points differ signif icantly from those of controls 
(p<o.ol). 
Discussion 
We present a paradigm of pharmacological adrenalectomy of fetal 
rat pups in utero. Metyrapone (which crosses the placenta) is 
injected into pregnant rats for 1-3 days, resulting in functional 
adrenalectomy in both mothers and pups. 
The efficacy of this regimen is evident from the dramatic 
alterations in both maternal and fetal serum corticosterone and 
ACTH. Corticosterone levels decrease to 5 mcg/dl, levels that have 
been reported in surgically adrenalectomized rats (6). As 
corticosterone crosses the placenta, it could be argued that only 
maternal adrenalectomy is achieved, and fetal levels reflect 
decreased maternal synthesis. It is well established, however, that 
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the fetal adrenal is relatively large and can secrete 
corticosterone during late fetal life (4), and that the majority 
of fetal plasma corticosterone is fetal-derived (5). Furthermore, 
surgical maternal adrenalectomy results in marked iDcrease in fetal 
plasma corticosterone, in an attempt to "compensate" for lack of 
maternal hormone (6). 
Consequent to adrenalectomy of the pregnant rat alone, fetal 
serum ACTH (a peptide which does not cross the placenta) should be 
unchanged (6), or decreased, due to negative feedback effect of 
hyperactive fetal adrenal. The observed elevation in fetal serum 
ACTH suggests elimination of steroid feedback, or stimulation of 
pituitary synthesis and release of this hormone at the brain or 
pituitary level. The fetal pituitary has been shown to produce ACTH 
in response to CRF during the late fetal period (7), and serum ACTH 
levels reported in this study are comparable to previous reports 
(5,6) . 
This model of pharmacological adrenalectomy is derived from the 
regimen proposed by Plotsky et al. (8). As in their adult model, 
it circumvents surgery-induced trauma and significant stress which, 
by themselves, affect the CRH-ACTH-adrenal axis. Moreover, 
metyrapone crosses the placenta and can thus block corticosterone 
synthesis in the fetal adrenal gland in a relatively specific 
manner: Since metyrapone is a l l -beta-hydroxylase blocker, the 
synthesis of rat mineralocorticoids and testosterone is not 
affected. 
We have modif ied Plotsky's pharmacological adrenalectomy regimen 
extensively to eliminate the increased toxicity in pregnant female 
rats. Using Plotsky's original doses of 20mg of metyrapone per 
100gm body weight every 8 hours resulted in maternal weight loss, 
and in fetal wasting or death. Our version does not affect fetal 
weight, l itter size, or the apparent well-being of fetuses, and can 
thus allow direct manipulation of the fetal brain-adrenal axis. The 
model of a pharmacological ly adrenalectomized fetal rat may thus 
serve as a tool to investigate mechanisms control l ing CRH gene 
expression. 
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